https://doi.org/10.55788/ed8d1bed
“Although restricting fluid is a common recommendation for patients with HF, evidence in this area is of low quality,” outlined Dr Roland van Kimmenade (Radboud University Medical Center, the Netherlands) [1]. That was the rationale for the FRESH-UP study (NCT04551729), which compared fluid restriction with liberal fluid intake in patients with chronic HF. Participants (n=504) were randomised 1:1 to fluid restriction, which comprised an advised maximum intake of 1,500 mL per day, or liberal fluid intake. The primary outcome was the health status at 3 months, as measured by the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS).
In the liberal fluid intake arm, the mean KCCQ-OSS score increased from 73.4 points at baseline to 74.0 points at 3 months. In the fluid restriction arm, there was a slight decline in this score from baseline (74.0) to 3 months (72.2 points). The adjusted mean difference between the study arms was 2.17 points, a non-significant difference (95% CI 0.06–4.39; P=0.06). Other health outcomes, such as death, all-cause hospitalisation, hospitalisation for HF, and acute kidney injury, did not display differences between the treatment groups either (see Table). However, participants in the fluid restriction group had significantly more thirst distress, as was assessed by the thirst distress scale in HF (16.9 vs 18.6; P<0.001).
Table: Secondary outcomes in FRESH-UP [1]

3M, 3 months; HF, heart failure.
“We did see a numerical benefit in KCCQ-OSS for patients in the fluid restriction arm, but this was not a significant difference,” Dr van Kimmenade summarised. “We did not see any differences between the 2 groups with respect to other health outcomes either, which makes us doubt the value of fluid restriction in patients with chronic HF.”
- Van Kimmenade RRJ, et al. Liberal fluid intake versus fluid restriction in chronic heart failure: the FRESH-UP study. Late-breaking Clinical Trials IV, ACC 2025 Scientific Session, 29–31 March, Chicago, USA.
Copyright ©2025 Medicom Medical Publishers
Posted on
Previous Article
« FAIR-HF2: The value of intravenous iron in patients with HF and iron deficiency Next Article
Potential benefit of autologous cell therapy in patients with ischaemic HFrEF? »
« FAIR-HF2: The value of intravenous iron in patients with HF and iron deficiency Next Article
Potential benefit of autologous cell therapy in patients with ischaemic HFrEF? »
Table of Contents: ACC 2025
Featured articles
Late-breaking Heart Failure Studies
Potential benefit of autologous cell therapy in patients with ischaemic HFrEF?
Restricting fluid in HF may not be necessary after all
FAIR-HF2: The value of intravenous iron in patients with HF and iron deficiency
MIGHTy-Heart: Can we improve transition-of-care in post-acute HF?
Dapagliflozin after TAVI reduces HF in elderly patients
Cardiometabolic and Vascular Disease
Oral semaglutide reduces cardiovascular events in patients at high-risk with type 2 diabetes
STRIDE: Semaglutide improves function, symptoms, and outcomes in patients with peripheral artery disease and type 2 diabetes
Lorundrostat represents novel class of BP-lowering drugs
ALLEPRE: Long-term benefits of nurse-led secondary prevention programme for ACS
Can we manage INOCA in women with intensive medical therapy?
Balancing Ischaemia and Bleeding Risk
API-CAT: Encouraging results for extended reduced-dose apixaban in cancer-related VTE
Rivaroxaban may be an alternative to warfarin in post-MI left ventricular thrombus
Clopidogrel may be preferred over aspirin in high-risk patients after PCI
Potentially practice-changing formulation for cardiac surgery-related bleeding?
Searching for the optimal duration of DAPT after PCI
REVERSE-IT: Bentracimab restores platelet function in ticagrelor users
Developments in Invasive Interventions
TAVR non-inferior to SAVR in low-risk aortic stenosis after 5 years
ALIGN-AR: Novel device for aortic regurgitation shows its potential
Routine use of cerebral embolic protection during TAVR not supported
TRILUMINATE: TEER procedure with TriClip device improves outcomes in patients with severe TR
FLAVOUR II: Novel non-invasive PCI-guidance strategy non-inferior to standard-of-care
More Topics
Results for a deep learning ECG model relative to clinical assessment and current biomarkers
Real-world performance of pulse oximeters may lead to health disparities
Digifab may decrease kidney injury in high-risk cardiac surgery patients
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com